LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Inicio・Lista de Acciones・Chimerix Inc

Chimerix Inc

Cerrado

Sector Salud

0.97 2.11

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.93

Máximo

0.97

Métricas clave
By Trading Economics
Ventas	4K
BPA	-0.2
Empleados	72

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+627.27 upside

Dividendos
By Dow Jones
Próximas Ganancias	7 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-3.6M 88M
Apertura anterior	-1.14
Cierre anterior	0.97

Noticias sobre sentimiento de mercado

By Acuity

16%

84%

30 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

0.78 / 0.843 Soporte y Resistencia

Chimerix Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 22:50 UTC

Acciones populares

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1 nov 2024, 22:43 UTC

Principales Movimientos del Mercado

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1 nov 2024, 22:13 UTC

Principales Movimientos del Mercado

Chewy Up 5% on S&P MidCap 400 Inclusion

1 nov 2024, 21:39 UTC

Ganancias

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2 nov 2024, 13:53 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov 2024, 13:44 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 13:00 UTC

Ganancias

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov 2024, 12:58 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:48 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov 2024, 12:32 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:28 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov 2024, 12:17 UTC

Ganancias

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Net $26.25B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2 nov 2024, 12:00 UTC

Ganancias

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2 nov 2024, 09:30 UTC

Principales Noticias

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

2 nov 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

1 nov 2024, 22:51 UTC

Ganancias

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1 nov 2024, 22:00 UTC

Principales Noticias

Ganancias

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1 nov 2024, 21:29 UTC

Principales Noticias

Ganancias

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1 nov 2024, 21:24 UTC

Ganancias

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Comparación entre iguales

Cambio de precio

Chimerix Inc Esperado

Precio Objetivo

By TipRanks

627.27% repunte

Estimación a 12 meses

Media 7.2 USD 627.27%

Máximo 11 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Chimerix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Chimerix Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.78 / 0.843Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

30 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Chimerix Inc

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.